13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002011932
Total reported value
$162.1M
$162.1M
63 檔
17.8%
According to the latest 13F quarterly dataset, Exome Asset Management LLC managed an equity portfolio of $162.1M at the end of Q2 2025, spanning 63 distinct U.S. exchange-listed positions.
During Q2 2025, Exome Asset Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TLT | iShares 20+ Year Treasury Bond ETF | ETF-Gov Bonds | 5.47% | — | — | |
| 2 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 4.99% | -1.75% | -6.02% | |
| 3 | GH | Guardant Health Inc | Stock-Healthcare | 3.80% | +2.30% | -22.80% | |
| 4 | GERN | Geron CORP | Stock-Other | 3.58% | +0.49% | NEW | |
| 5 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.56% | +0.04% | -10.69% | |
| 6 | THC | Tenet Healthcare CORP | Stock-Healthcare | 3.53% | — | — | |
| 7 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.92% | — | -12.82% | |
| 8 | COGT | Cogent Biosciences Inc | Stock-Other | 2.85% | -0.51% | -14.16% | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.85% | -0.38% | +11.92% | |
| 10 | REPL | Replimune Group Inc | Stock-Other | 2.75% | +0.28% | NEW | |
| 11 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.71% | +0.72% | — | |
| 12 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.59% | -1.07% | EXIT | |
| 13 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.57% | -0.32% | — | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 2.42% | — | -0.49% | |
| 15 | NTRA | Natera Inc | Stock-Healthcare | 2.34% | +0.38% | — | |
| 16 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.32% | — | -23.30% | |
| 17 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 2.28% | — | -35.43% | |
| 18 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.22% | — | — | |
| 19 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.15% | — | -8.57% | |
| 20 | VSTM | Verastem Inc | Stock-Other | 1.85% | -0.74% | — | |
| 21 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.84% | -1.96% | — | |
| 22 | PEN | Penumbra Inc | Stock-Healthcare | 1.72% | +0.16% | — | |
| 23 | ETNBGBP | 89bio Inc | Stock-Other | 1.70% | — | -34.04% | |
| 24 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.69% | — | +29.88% | |
| 25 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.63% | — | +16.95% | |
| 26 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.50% | — | — | |
| 27 | ✓ | Stock-Other | 1.44% | — | — | ||
| 28 | WAY | Waystar Holding CORP | Stock-Other | 1.43% | — | — | |
| 29 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.42% | -0.07% | -4.27% | |
| 30 | TXG | 10x Genomics Inc-class A | Stock-Other | 1.41% | +0.74% | — | |
| 31 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.39% | — | -24.17% | |
| 32 | RGNX | Regenxbio Inc | Stock-Other | 1.38% | — | -44.22% | |
| 33 | UHS | Universal Health Services-b | Stock-Healthcare | 1.36% | — | — | |
| 34 | VERA | Vera Therapeutics Inc | Stock-Other | 1.34% | +0.19% | — | |
| 35 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.34% | — | +22.23% | |
| 36 | COR | Cencora Inc | Stock-Healthcare | 1.34% | — | — | |
| 37 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.27% | -1.78% | EXIT | |
| 38 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.21% | — | +74.23% | |
| 39 | ✓ | Travere Therapeutics Inc | Stock-Other | 1.21% | — | — | |
| 40 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.15% | — | +185.29% | |
| 41 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.13% | — | — | |
| 42 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.10% | — | — | |
| 43 | SRPT 1.25 09-15-27Bond | Sarepta Therapeutics Inc | Bond | 1.07% | — | — | |
| 44 | ✓ | Ultragenyx Pharmaceutical In | Stock-Other | 1.01% | — | — | |
| 45 | GOSS | Gossamer Bio Inc | Stock-Other | 1.00% | — | — | |
| 46 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.83% | — | -47.79% | |
| 47 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.77% | — | — | |
| 48 | MBX | Mbx Biosciences Inc | Stock-Other | 0.54% | — | -52.61% | |
| 49 | ALVO | Alvotech | Stock-Other | 0.53% | — | -13.02% | |
| 50 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.49% | — | — |
According to official SEC Form 13F filings, Exome Asset Management LLC reported a total U.S. public equity portfolio value of $162.1M across 63 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TLT, BBIO, GH) accounted for 17.8% of total reported equity market value during Q2 2025.
During Q2 2025, Exome Asset Management LLC's top holdings by market value included TLT (5.5%)、BBIO (5.0%)、GH (3.8%). The largest single position, TLT, represented 5.5% of total portfolio value.
In Q2 2025, Exome Asset Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.